Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus HALOTESTIN.
ANDROID 10 vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen
Androgen